Jae-ho A. Yoon

Seoul St. Mary's Hospital
Seoul, Republic of Korea

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 179 publications

Adult-onset activated PI3Kδ syndrome presenting with HLH-like hyperinflammation, autoimmunity, and thrombosis: an underrecognized inborn error of immunity.

Adult-onset activated PI3Kδ syndrome presenting with HLH-like hyperinflammation, autoimmunity, and thrombosis: an underrecognized inborn error of immunity.

Journal: Haematologica

Published: May 27, 2026

Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study.

Real-world clinical outcomes of tisagenlecleucel in relapsed or refractory diffuse large B-cell lymphoma: a single-center retrospective study.

Journal: Frontiers in oncology

Published: March 05, 2026

Clinical Impact of Discordant Minimal Residual Disease Assessment in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Clinical Impact of Discordant Minimal Residual Disease Assessment in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: February 02, 2026

Clinical Impact of Discordant Minimal Residual Disease Assessment in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Clinical Impact of Discordant Minimal Residual Disease Assessment in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: February 02, 2026

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

Ianalumab plus Eltrombopag in Immune Thrombocytopenia.

Journal: The New England journal of medicine

Published: December 09, 2025

Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: realworld efficacy and risks of early ponatinib dose reduction.

Frontline ponatinib plus hyper-CVAD over imatinib in adults with Ph-positive acute lymphoblastic leukemia: realworld efficacy and risks of early ponatinib dose reduction.

Journal: Haematologica

Published: October 24, 2025

Real-World Effectiveness of Recombinant Zoster Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients.

Real-World Effectiveness of Recombinant Zoster Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients.

Journal: Transplantation and cellular therapy

Published: October 10, 2025

Author Response to: Comment on Factors Affecting Haploidentical Transplant Outcomes with Post-Transplant Cyclophosphamide Plus Anti-Thymocyte Globulin.

Author Response to: Comment on Factors Affecting Haploidentical Transplant Outcomes with Post-Transplant Cyclophosphamide Plus Anti-Thymocyte Globulin.

Journal: Transplantation and cellular therapy

Published: September 17, 2025

Real-World Outcomes of Tisagenlecleucel Versus Standard-of-Care Salvage Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis From Korea.

Real-World Outcomes of Tisagenlecleucel Versus Standard-of-Care Salvage Chemotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: A Propensity Score-Matched Analysis From Korea.

Journal: Journal of Korean medical science

Published: September 11, 2025

Relapse patterns focusing on central nervous system involvement after allogeneic hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia.

Relapse patterns focusing on central nervous system involvement after allogeneic hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia.

Journal: Bone marrow transplantation

Published: August 30, 2025

Predicting treatment-free remission after thrombopoietin receptor agonist therapy in immune thrombocytopenia: real-world outcomes from a Korean cohort.

Predicting treatment-free remission after thrombopoietin receptor agonist therapy in immune thrombocytopenia: real-world outcomes from a Korean cohort.

Journal: Journal of thrombosis and haemostasis : JTH

Published: July 27, 2025

Prognostic factors and outcomes of tisagenlecleucel in relapsed or refractory B-cell malignancies: a single-center real-world study.

Prognostic factors and outcomes of tisagenlecleucel in relapsed or refractory B-cell malignancies: a single-center real-world study.

Journal: Cytotherapy

Published: July 14, 2025

Showing 1-12 of 179

Last Updated: 09/26/2026